FLT3 and acute myeloid leukemia: Decades of preclinical and clinical work culminated in the approval of three potent FLT3 inhibitors—midostaurin, gilteritinib, and quizartinib—that, together with stem cell transplantation, have dramatically improved outcomes for patients with FLT3-mutant AML.